Cetera Investment Advisers Acquires 3,345 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cetera Investment Advisers grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 16.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 23,107 shares of the life sciences company's stock after acquiring an additional 3,345 shares during the period. Cetera Investment Advisers' holdings in Illumina were worth $3,088,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Capital World Investors raised its stake in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. increased its position in Illumina by 54,220.9% in the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after buying an additional 1,909,118 shares during the period. Norges Bank acquired a new position in Illumina during the 4th quarter valued at $228,714,000. Bessemer Group Inc. lifted its stake in shares of Illumina by 32,837.5% in the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after buying an additional 1,344,038 shares during the period. Finally, WCM Investment Management LLC lifted its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 1.5%

NASDAQ ILMN traded up $1.26 during trading hours on Tuesday, hitting $84.21. The company's stock had a trading volume of 1,984,525 shares, compared to its average volume of 2,315,711. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The firm has a market capitalization of $13.33 billion, a P/E ratio of -10.96, a PEG ratio of 1.60 and a beta of 1.35. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a fifty day moving average of $78.46 and a 200 day moving average of $110.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the business posted $0.98 EPS. The firm's quarterly revenue was down 1.4% on a year-over-year basis. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the purchase, the chief financial officer now owns 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ILMN shares. Canaccord Genuity Group dropped their target price on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a report on Monday, May 12th. Royal Bank of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Stephens reissued an "overweight" rating and issued a $105.00 target price on shares of Illumina in a report on Tuesday. Guggenheim dropped their price target on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Robert W. Baird reduced their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus price target of $128.15.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.